Destiny Pharma plc products

A Phase 2b clinical study, which was a multi-centre, randomized, placebo-controlled study of XF-73 nasal gel as a new product for the prevention of the incidence of post-surgical infections such as methicillin-resistant Staphylococcus aureus (MRSA) completed recruitment at the end of 2020 and top-line results were reported in Q1 2021, as planned.

There are two XF-73 dermal programmes in development. One is being run by our China partner and shareholder – China Medical Systems Holdings Limited (CMS) – focused on superficial skin infections and the other is an in-house programme looking at the use of XF-73 for the prevention and treatment of serious infections associated with burns and open wounds such as diabetic foot ulcers (DFUs). The latter programme is in collaboration with the US government’s National Institute of Allergy and Infectious Diseases (NIAID).